Navigating Your Journey: What is the Starting Dose for Zepbound?

Last reviewed: June 19, 2026

Last updated: June 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The Zepbound prescribing information states that the recommended starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for four weeks, and it is explicit that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. After those four weeks the labeled schedule increases to 5 mg once weekly, with further increases in 2.5 mg increments after at least four weeks on the current dose. What the label describes is a framework; where any individual actually lands within it is a decision their prescriber makes based on response and tolerability, and nothing you read online can substitute for that.

What the Labeled Schedule Says

Zepbound is a glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist — a dual receptor agonist, not a GLP-1 agonist alone. It is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

For both indications the labeled starting dosage is the same: 2.5 mg once weekly for four weeks. The recommended maintenance dosages differ by indication — 5 mg, 10 mg, or 15 mg once weekly for weight reduction and long-term maintenance, and 10 mg or 15 mg once weekly for obstructive sleep apnea. The maximum recommended dosage is 15 mg once weekly.

Why It Starts Low

The label states the reason directly: the escalation schedule exists to reduce the risk of gastrointestinal adverse reactions. Those reactions are the dominant tolerability issue with incretin therapies. In the pooled weight-reduction trials, gastrointestinal adverse reactions occurred in 56 percent of patients at each of the 5 mg, 10 mg, and 15 mg dosages versus 30 percent with placebo.

The individual reaction rates track the same pattern. Nausea was reported in 25, 29, and 28 percent of patients at 5 mg, 10 mg, and 15 mg respectively versus 8 percent with placebo; diarrhea in 19, 21, and 23 percent versus 8 percent; vomiting in 8, 11, and 13 percent versus 2 percent. Starting at a maintenance dose would front-load all of that.

2.5 mg Is Not a Maintenance Dose

This is the point most often lost. The labeling says plainly that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. It is a ramp, not a destination. The efficacy figures associated with Zepbound come from the 5, 10, and 15 mg dosages studied in the registration program.

It is also worth noting there is no 0.25 mg tirzepatide strength. That figure belongs to semaglutide, whose labeled initiation dosage is 0.25 mg once weekly. Confusing the two is common and consequential, because the molecules, the strengths, and the escalation intervals are all different.

The Escalation Is a Framework, Not a Countdown

The label directs that after four weeks the dosage increase to 5 mg once weekly, and that it may then be increased in 2.5 mg increments after at least four weeks on the current dose. It further instructs prescribers to consider treatment response and tolerability when selecting the maintenance dosage, and to consider a lower maintenance dosage if a patient does not tolerate one.

Notice the language: "at least" four weeks, and "consider." The schedule sets minimum intervals and a ceiling, but the pace and endpoint within it are clinical judgments. Two people can follow the same label and settle at different maintenance dosages, and both can be correct.

What Was Studied at the Maintenance Dosages

The pivotal obesity trial, Tirzepatide Once Weekly for the Treatment of Obesity, ran 72 weeks in 2,539 adults and reported mean weight changes of −15.0, −19.5, and −20.9 percent across the three dosages studied versus −3.1 percent with placebo. In the later head-to-head trial published as Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, 751 adults with obesity and without type 2 diabetes were randomized to the maximum tolerated dose of each drug for 72 weeks, with least-squares mean weight change of −20.2 percent for tirzepatide versus −13.7 percent for semaglutide.

Those trials also illustrate the point about maintenance dosing: participants were titrated to a maximum tolerated dose, not assigned a fixed one. Tolerability was built into the design.

Handling and Presentation Questions Belong to Your Pharmacy

Zepbound is supplied in several presentations — cartons of four prefilled single-dose pens, single-dose vials in one- and four-packs, a multi-dose vial, and a single-patient-use KwikPen. The label instructs that patients be informed which presentation they will receive and that they receive training appropriate for that specific presentation.

That instruction is the reason practical questions about preparation, injection, and storage are not answerable in the abstract. The correct procedure depends on which device is in your hands. Your dispensed Instructions for Use and your pharmacist are the authoritative sources.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

What is the starting dose for Zepbound?

The Zepbound prescribing information states that the recommended starting dosage for all indications is 2.5 mg injected subcutaneously once weekly for four weeks. The label is explicit that 2.5 mg is for treatment initiation and is not approved as a maintenance dosage. After four weeks the labeled schedule increases to 5 mg once weekly, with further increases in 2.5 mg increments after at least four weeks on the current dose.

What are the maintenance dosages for Zepbound?

For weight reduction and long-term maintenance, the recommended maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly. For moderate to severe obstructive sleep apnea in adults with obesity, they are 10 mg or 15 mg once weekly. The maximum recommended dosage is 15 mg once weekly. The label directs prescribers to consider response and tolerability when selecting a maintenance dosage.

Why does Zepbound start at a low dose?

The labeling states the escalation schedule is intended to reduce the risk of gastrointestinal adverse reactions. In the pooled weight-reduction trials, gastrointestinal adverse reactions occurred in 56 percent of patients at each of the 5, 10, and 15 mg dosages compared with 30 percent on placebo. Nausea, diarrhea, vomiting, and constipation were the most frequently reported individual reactions.

Is there a 0.25 mg dose of tirzepatide?

No. Tirzepatide products start at 2.5 mg. The 0.25 mg figure is the labeled initiation dosage for semaglutide, a different molecule with different strengths and a different escalation interval. Mixing the two is a common error and a consequential one, since the medications are not interchangeable in strength, schedule, or labeled indication.

How much weight was lost at the studied Zepbound dosages?

The pivotal 72-week obesity trial in 2,539 adults reported mean weight changes of −15.0, −19.5, and −20.9 percent across the three dosages studied versus −3.1 percent with placebo. A later 72-week head-to-head trial in 751 adults with obesity and without type 2 diabetes reported least-squares mean weight change of −20.2 percent with tirzepatide versus −13.7 percent with semaglutide, using maximum tolerated doses of each.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.